The historical rank and industry rank for AFT Pharmaceuticals's FCF Margin % or its related term are showing as below:
NZSE:AFT'
s FCF Margin % Range Over the Past 10 Years
Min: -27.72 Med: -0.63 Max: 9.96
Current: -7.68
During the past 11 years, the highest FCF Margin % of AFT Pharmaceuticals was 9.96%. The lowest was -27.72%. And the median was -0.63%.
NZSE:AFT's FCF Margin % is ranked worse than 70.56% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NZSE:AFT: -7.68
AFT Pharmaceuticals FCF Margin % Related Terms
AFT Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (NZSE:AFT) has a FCF Margin % of -11.82% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #676 out of 958 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is AFT Pharmaceuticals' FCF Margin % too high?
AFT Pharmaceuticals' current FCF Margin % is -11.82%. Based on the distribution chart, AFT Pharmaceuticals ranks #676 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #676 out of 958 companies for FCF Margin %. This places AFT Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current FCF Margin % is -11.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.15, compared to a current price of NZ$3.68 — trading 11.3% below its estimated fair value. The current FCF Margin % is -11.82%. AFT Pharmaceuticals' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current FCF Margin % is -11.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.68 is trading 11.3% below its estimated GF Value™ of NZ$4.15.
GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NZSE:AFT:
FCF Margin %: -11.82%
GF Value™: NZ$4.15 vs. price of NZ$3.68 (11.3% below fair value)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
96GF Score
Get the complete analysis for NZSE:AFT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
